Clinical trials: ICAD - Intracranial Atherosclerotic Disease
- Condition ICAD - Intracranial Atherosclerotic Disease
- Funder type Industry (pharma, biotech, devices)
Atherosclerosis Cerebral Infarction
Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
Randomized, control, open label, multicentre clinical study. The patient who are in accordance with subject inclusion and exclusion criteria will be randomized to A group: Routine treatment B group: Routine treatment+ Cilostazol…
- Trial name
- NCT00823875
- Testing
- Cilostazol group, Probucol group, Cilostazol + Probucol group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Otsuka Beijing Research Institute
Cerebral Ischemia, Cerebral Atherosclerosis
DEB for Symptomatic Intracranial Atherosclerosis Stenosis
A prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.
- Trial name
- NCT04821726
- Testing
- Drug eluting balloon (Vmoky)
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Yinyi(Liaoning) Biotech Co., Ltd.
Intracranial Atherosclerosis
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
The IRISS study is designed to collect clinical and angiographic outcomes data when stenting intracranial atherosclerotic lesions using the Wingspan™ Stent System with Gateway™ PTA Balloon Catheter in routine clinical practice.
- Trial name
- IRISS (NCT00929383)
- Testing
- Wingspan Stent System with Gateway PTA Balloon Catheter
- Where
- 19 sites in France, Germany
- Volunteers
- 82 people
- Sponsor
- Stryker Neurovascular
Cerebral Atherosclerosis
Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
The purpose of this study is to obtain additional data on efficacy and safety of Divaza for adjustment of oxidative disorders in patients with cerebral atherosclerosis.
- Trial name
- NCT03485495
- Testing
- Divaza
- Where
- 10 sites in Russia
- Volunteers
- 124 people
- Sponsor
- Materia Medica Holding